Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02235233 · ClinicalTrials.gov registry record · Phase 1
Effect of Non-Alcoholic Steatohepatitis (NASH) on the Pharmacokinetics of 99mTechnetium-Mebrofenin
A Phase 1 study, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT02235233 is a Phase 1 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 21 participants.
The verdict
NCT02235233, a Phase 1 study, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This study is designed to investigate the effect of NASH (non-alcoholic steatohepatitis) on the disposition of 99mTechnetium(Tc)-mebrofenin and to relate changes in 99mTc-mebrofenin disposition to differences in the bile acid profile and Fibroscan Fibrosis Score of healthy subjects compared to patients with NASH.
Interventions
- DRUG Technetium Tc 99M Mebrofenin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2015-04 |
| Est. Completion | 2016-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02235233
The ClinicalTrials.gov registry entry for NCT02235233 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Technetium Tc 99M Mebrofenin is the first listed.
NCT02235233 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02235233 about?
NCT02235233 is a clinical study titled "Effect of Non-Alcoholic Steatohepatitis (NASH) on the Pharmacokinetics of 99mTechnetium-Mebrofenin". This study is designed to investigate the effect of NASH (non-alcoholic steatohepatitis) on the disposition of 99mTechnetium(Tc)-mebrofenin and to relate changes in 99mTc-mebrofenin disposition to differences in the bile acid profile and Fibroscan Fibrosis Score of healthy subjects compared to patie...
What is the current status of trial NCT02235233?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2015-04. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02235233?
The interventions under investigation include: Technetium Tc 99M Mebrofenin (DRUG).
Who is sponsoring clinical trial NCT02235233?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.